Innate: start of a Phase 1 study for an ADC

(CercleFinance.com) - Innate Pharma announces that the first patient has been treated in a Phase 1 clinical trial evaluating the safety and tolerability profile of IPH4502, a novel antibody-drug conjugate (ADC) in advanced solid tumors known to express Nectin-4.


Involving approximately 105 patients, this open-label, multi-center study will include a part 1 dose escalation and a part 2 dose optimization arm, and will evaluate the safety, tolerability and preliminary efficacy of IPH4502 as a single agent.

Among the advanced solid tumors known to express Nectin-4, Innate Pharma cites urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal and colorectal cancers.

Copyright (c) 2025 CercleFinance.com. All rights reserved.